Clinical Trial

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-09.
Status change: Not Yet Recruiting → Recruiting 2025-11-16
Trial Details
NCT Number NCT07175220
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Locally Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment 200 participants
Start Date 2025-10-09
Primary Completion 2028-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-18